PBS approval process goes west with new FTA
One of these drugs, Zyprexa, has been linked to a significant increase in the risk of diabetes amongst people taking it. In fact, it's dubious improved efficacy (as compared to similar drugs) and it's price (twice that of older drugs) are the centrepiece of allegations regarding ties between it's manufacturer, Eli-Lilly and the Bush Adminstration.
The other drug, risperdal consta, is an older(introduced in the 1990's) anti-psychotic in a new long acting form.It uses an innovative new form of sustained release encapsulation which enables it to be given up fortnightly instaed of daily. But, although, it is an 'atypical anti-psychotic' it still has typical symptoms that it shares with the older anti-psychotics such as librium and haloperidol. Anecdotal evidence suggests that it is the most likely of these newer anti-psychotics to have 'extra-pyramidal syndromes'. These are involuntary movements, that can be quite severe and can lead to permanent disabilities.
Whilst one can make out a case for the latter drug(the long acting formulation is an innovation), the case for zyprexa is surely contentious. Is this a sign of things to come?